Oxford and AstraZeneca begin trials of their vaccine for the first time in children

The English university of Oxford has begun this Saturday to test its vaccine against Covid-19, developed together with the pharmaceutical company Astrazeneca, in children 6 to 17 years. Until now, minors of that age group had not been included in the vaccine tests, so they are the world’s first trials for this population and they will determine the effects and efficacy of vaccines in children.

In a statement, the researchers explain that tests to determine the safety and immune response of children to the vaccine known technically as ChAdOx1 nCoV-19 will be developed in centers in the cities of Oxford, London, Southampton and Bristol. For these trials, we will recruit 300 volunteers, of which up to 240 will receive the vaccine from Oxford / AstraZeneca and the rest a control vaccine against meningitis.

According to the University of Oxford, these are the first trials with young children of a vaccine against covid, since so far only they have been done tests with 16 and 17 year oldsWithout any preparation being authorized for public use at the moment.

Coronavirus vaccination in Catalonia

Oxford Lead Researcher and Childhood Immunity and Infection Expert, Andrew Pollard, said that although children appear to be less affected by the coronavirus and they are not likely to become seriously ill, “It is important to establish the safety and immune response” to the vaccine, as some minors may “benefit from being immunized.”

The Oxford / AstraZeneca vaccine is, together with that of Moderna and Pfizer / BioNTech, one of the three that, at the moment, administered in the UK, which aims to meet next Monday the goal of having vaccinated the four most vulnerable groups in society, some 15 million people.

In previous studies with adults, it has been shown that the British preparation, which is also distributed in the European Union and will be offered at cost to developing countries, 63% effective, inoculated in two separate doses for eight to 12 weeks, and its efficacy against new variants of the virus is currently being investigated


Source: LA INFORMACIÓN – Lo último by www.lainformacion.com.

*The article has been translated based on the content of LA INFORMACIÓN – Lo último by www.lainformacion.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!